Oppenheimer Maintains Outperform, $27 PT on Body Central

Oppenheimer reiterates its Outperform rating and $27 price target on Body Central

as the company had a strong finish to the year. Oppenheimer says, " BODY pre-announced 4Q revenues and updated EPS guidance. 4Q revenues of $80.7M compare to consensus of $79.3M and $67.1M last year, and are above most recent guidance of $75M-$79M. Projected 4Q EPS of $0.36-$0.37 vs. $0.18 LY is in line with consensus of $0.37 and at the high-end of recent $0.34-$0.37 guidance. We believe these results are especially impressive given increased competitive landscape as retailers had heightened promotions with price points at/approaching BODY's sweet spot. Clearly, its differentiated product strategy continues to resonate with its loyal customer base as well as customers in new area." Body closed at $23.86 per share on Monday.